CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: TYK2 (ImmuneEditome ID:7297)

1. Gene summary of enriched editing regions for TYK2

check button Gene summary
Gene informationGene symbol

TYK2

Gene ID

7297

GeneSynonymsIMD35|JTK1
GeneCytomap

19p13.2

GeneTypeprotein-coding
GeneDescriptionnon-receptor tyrosine-protein kinase TYK2
GeneModificationdate20230518
UniprotIDP29597;A0A024R7E4;K7EJR6;E9PM19
PubMed ID

36834806

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:10351193-10352385:-ENST00000524470.1ENSG00000105397.12TYK2ncRNA_exonicAluSg,AluSq2,AluYm1,MIR,(CTTT)nchr19:10351193-10352385:-.alignment
chr19:10351193-10352385:-ENST00000529422.1ENSG00000105397.12TYK2ncRNA_exonicAluSg,AluSq2,AluYm1,MIR,(CTTT)nchr19:10351193-10352385:-.alignment
chr19:10351193-10352385:-ENST00000592137.1ENSG00000105397.12TYK2ncRNA_exonicAluSg,AluSq2,AluYm1,MIR,(CTTT)nchr19:10351193-10352385:-.alignment
chr19:10358306-10359029:-ENST00000264818.9ENSG00000105397.12TYK2intronicAluJb,AluJr,AluSgchr19:10358306-10359029:-.alignment
chr19:10358306-10359029:-ENST00000524462.4ENSG00000105397.12TYK2intronicAluJb,AluJr,AluSgchr19:10358306-10359029:-.alignment
chr19:10358306-10359029:-ENST00000525621.4ENSG00000105397.12TYK2intronicAluJb,AluJr,AluSgchr19:10358306-10359029:-.alignment
chr19:10358306-10359029:-ENST00000529370.4ENSG00000105397.12TYK2intronicAluJb,AluJr,AluSgchr19:10358306-10359029:-.alignment
chr19:10358306-10359029:-ENST00000533334.1ENSG00000105397.12TYK2intronicAluJb,AluJr,AluSgchr19:10358306-10359029:-.alignment
chr19:10362903-10364437:-ENST00000264818.9ENSG00000105397.12TYK2intronicAluSx1,AluJb,AluSq2chr19:10362903-10364437:-.alignment
chr19:10362903-10364437:-ENST00000524462.4ENSG00000105397.12TYK2intronicAluSx1,AluJb,AluSq2chr19:10362903-10364437:-.alignment
chr19:10362903-10364437:-ENST00000525220.1ENSG00000105397.12TYK2intronicAluSx1,AluJb,AluSq2chr19:10362903-10364437:-.alignment
chr19:10362903-10364437:-ENST00000525621.4ENSG00000105397.12TYK2intronicAluSx1,AluJb,AluSq2chr19:10362903-10364437:-.alignment
chr19:10362903-10364437:-ENST00000529370.4ENSG00000105397.12TYK2intronicAluSx1,AluJb,AluSq2chr19:10362903-10364437:-.alignment
chr19:10368898-10369898:-ENST00000530829.1ENSG00000105397.12TYK2exonicAluY,MLT1J2,AluSx,AluJrchr19:10368898-10369898:-.alignment


Top

2. Tumor-specific enriched editing regions for TYK2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr19:10351193-10352385:-HNSCCliEER1.7417e-021.3986e-02-0.3326image
ENSG00000105397.12,TYK2KIRPCliEAG1.4279e-021.5480e-020.3589image
chr19:10351193-10352385:-KIRPCliEER1.4279e-021.5480e-020.3589image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for TYK2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:10351193-10352385:-THYMEERENSG00000254614,AP003068.230.38392.4669e-035.1698e-060.4421imageNNNAT_cells_gamma_deltaGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr19:10351193-10352385:-THYMEERENSG00000254614,AP003068.230.38392.4669e-035.1698e-060.4421imageNNNAT_cells_gamma_deltaGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr19:10351193-10352385:-THYMEERENSG00000254614,AP003068.230.38392.4669e-035.1698e-060.4421imageNNNAT_cells_gamma_deltaGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

More results



Top

4. Enriched editing regions and immune related splicing for TYK2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:10351193-10352385:-
THYMEERMEXENSG00000129657.10chr1777213917:77215948:77215971:77216036:77216062:77216387:77216413:772168020.19534.7239e-027.2670e-050.4364imageNNNA
chr19:10351193-10352385:-
THYMEERMEXENSG00000129657.10chr1777213917:77215779:77215857:77216036:77216049:77216387:77216413:772168020.18444.3327e-027.5269e-050.4382imageNNNA
ENSG00000105397.12,TYK2
THYMEAGMEXENSG00000129657.10chr1777215922:77215948:77216010:77216036:77216062:77216387:77216413:772168020.21541.5351e-024.2885e-050.4486imageNACIN1;ADAR;AIFM1;ALKBH5;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZNF184NA
ENSG00000105397.12,TYK2
THYMEAGMEXENSG00000129657.10chr1777215909:77215922:77215984:77216036:77216062:77216387:77216413:772168020.20012.6059e-021.2491e-050.4754imageNACIN1;ADAR;AIFM1;ALKBH5;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZNF184NA
ENSG00000105397.12,TYK2
THYMEAGIRENSG00000157992.8chr227443397:27444061:27444185:27444297-0.39776.7946e-034.0121e-06-0.4668imageNADAR;BCCIP;BUD13;CPSF6;CSTF2T;DDX42;DDX54;DKC1;EIF4A3;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LIN28A;LIN28B;LSM11;NOP58;PCBP2;PRPF8;RBFOX2;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SRSF1;SRSF7;SRSF9;TAF15;TIA1;TRA2A;U2AF1;U2AF2;XRN2;ZNF184NAT_cells_CD4_naiveGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr19:10351193-10352385:-
THYMEERMEXENSG00000129657.10chr1777215753:77215766:77215971:77216036:77216049:77216387:77216413:772168020.20042.7869e-022.8004e-060.5022imageNNNAMacrophages_M1
chr19:10351193-10352385:-
THYMEERIRENSG00000157992.8chr227443397:27444061:27444185:27444297-0.38709.9239e-036.3054e-06-0.4606imageNNNAT_cells_CD4_naiveGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr19:10351193-10352385:-
THYMEERMEXENSG00000129657.10chr1777215922:77215935:77215971:77216036:77216049:77216387:77216413:772168020.21621.5561e-022.8776e-060.5046imageNNNA
chr19:10351193-10352385:-
THYMEERIRENSG00000161265.10chr1935743154:35743208:35743295:35743345-0.31473.9872e-028.7964e-05-0.4218imageNNNANK_cells_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr19:10351193-10352385:-
THYMEERMEXENSG00000129657.10chr1777215922:77215948:77216010:77216036:77216062:77216387:77216413:772168020.21971.2256e-024.2897e-050.4486imageNNNA

More results



Top

5. Enriched editing regions and immune infiltration for TYK2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:10351193-10352385:-ACCEERDendritic_cells_activated2.8423e-020.4218image
ENSG00000105397.12,TYK2ACCEAGDendritic_cells_activated2.8423e-020.4218image
chr19:10351193-10352385:-BLCAEERT_cells_gamma_delta1.4057e-020.1963image
ENSG00000105397.12,TYK2BLCAEAGT_cells_gamma_delta3.2672e-020.1706image
chr19:10351193-10352385:-BRCAEERT_cells_follicular_helper1.4436e-020.1777image
ENSG00000105397.12,TYK2BRCAEAGMonocytes1.1068e-020.1816image
chr19:10351193-10352385:-CESCEERT_cells_CD4_naive1.1017e-020.2190image
ENSG00000105397.12,TYK2CESCEAGT_cells_CD4_naive1.0324e-020.2201image
ENSG00000105397.12,TYK2COADEAGDendritic_cells_activated8.5534e-030.4153image
chr19:10351193-10352385:-ESCAEERB_cells_memory3.3962e-030.3257image
chr19:10358306-10359029:-ESCAEERT_cells_CD4_memory_resting1.0774e-02-0.3074image
chr19:10362903-10364437:-ESCAEERMast_cells_resting4.2638e-020.2583image
ENSG00000105397.12,TYK2ESCAEAGT_cells_CD4_naive1.4838e-030.2968image
chr19:10351193-10352385:-GBMEERT_cells_CD4_memory_resting7.3930e-040.3590image
ENSG00000105397.12,TYK2GBMEAGT_cells_CD4_memory_resting1.3339e-030.3425image
chr19:10351193-10352385:-HNSCEERNK_cells_resting4.6139e-020.2701image
ENSG00000105397.12,TYK2HNSCEAGNK_cells_resting4.0417e-020.2723image
chr19:10351193-10352385:-KICHEERT_cells_CD4_memory_activated7.4132e-030.5544image
ENSG00000105397.12,TYK2KICHEAGT_cells_CD4_memory_activated7.4132e-030.5544image
chr19:10351193-10352385:-KIRCEERMacrophages_M27.7191e-03-0.2243image
ENSG00000105397.12,TYK2KIRCEAGMacrophages_M24.8864e-03-0.2366image
chr19:10351193-10352385:-KIRPEERT_cells_regulatory_(Tregs)1.5540e-02-0.2924image
ENSG00000105397.12,TYK2KIRPEAGT_cells_regulatory_(Tregs)1.5540e-02-0.2924image
chr19:10351193-10352385:-LAMLEERDendritic_cells_activated4.7059e-02-0.3430image
ENSG00000105397.12,TYK2LAMLEAGT_cells_CD84.7418e-050.3714image
chr19:10351193-10352385:-LGGEERT_cells_gamma_delta1.2290e-020.1982image
ENSG00000105397.12,TYK2LGGEAGT_cells_gamma_delta1.1131e-020.1990image
ENSG00000105397.12,TYK2LUSCEAGMacrophages_M03.3443e-020.1682image
chr19:10351193-10352385:-OVEERMonocytes2.6722e-02-0.2023image
chr19:10362903-10364437:-OVEERDendritic_cells_resting4.0534e-060.6574image
chr19:10351193-10352385:-PAADEERT_cells_CD4_memory_resting1.2571e-020.3540image
ENSG00000105397.12,TYK2PAADEAGT_cells_CD4_memory_resting1.2571e-020.3540image
chr19:10351193-10352385:-PCPGEERB_cells_memory1.3900e-02-0.3958image
ENSG00000105397.12,TYK2PCPGEAGB_cells_memory1.4081e-02-0.3951image
chr19:10351193-10352385:-PRADEERDendritic_cells_activated4.3836e-030.3818image
ENSG00000105397.12,TYK2PRADEAGDendritic_cells_activated4.5491e-030.3770image
chr19:10351193-10352385:-SKCMEERMacrophages_M08.5885e-030.3097image
ENSG00000105397.12,TYK2SKCMEAGMacrophages_M08.4278e-030.3083image
chr19:10351193-10352385:-STADEERT_cells_regulatory_(Tregs)4.9017e-03-0.2834image
chr19:10358306-10359029:-STADEERMacrophages_M02.8874e-020.2255image
chr19:10362903-10364437:-STADEERDendritic_cells_resting1.4891e-02-0.2821image
chr19:10368898-10369898:-STADEERMacrophages_M21.0968e-02-0.4308image
ENSG00000105397.12,TYK2STADEAGDendritic_cells_resting2.0032e-03-0.2375image
chr19:10351193-10352385:-THYMEERT_cells_CD4_naive1.0140e-02-0.2586image
ENSG00000105397.12,TYK2THYMEAGT_cells_CD4_naive1.2986e-02-0.2489image
ENSG00000105397.12,TYK2UCECEAGB_cells_memory4.4335e-020.2628image
chr19:10351193-10352385:-UCSEEREosinophils9.9833e-040.6288image
ENSG00000105397.12,TYK2UCSEAGEosinophils9.8845e-040.6292image


Top

6. Enriched editing regions and immune gene sets for TYK2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr19:10351193-10352385:-ACCGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER4.6749e-030.5277image
ENSG00000105397.12,TYK2ACCGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG4.6749e-030.5277image
ENSG00000105397.12,TYK2BLCAGSVA_HALLMARK_MYC_TARGETS_V2EAG4.7092e-02-0.1587image
chr19:10351193-10352385:-BLCAGSVA_HALLMARK_MITOTIC_SPINDLEEER2.9615e-02-0.1742image
ENSG00000105397.12,TYK2BRCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG5.6101e-030.1977image
chr19:10351193-10352385:-BRCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER3.2957e-030.2127image
ENSG00000105397.12,TYK2COADGSVA_HALLMARK_HEME_METABOLISMEAG4.1375e-02-0.3282image
ENSG00000105397.12,TYK2DLBCGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG2.2391e-020.4460image
chr19:10351193-10352385:-ESCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER2.6498e-020.2496image
chr19:10358306-10359029:-ESCAGSVA_HALLMARK_PROTEIN_SECRETIONEER4.2173e-020.2471image
ENSG00000105397.12,TYK2ESCAGSVA_HALLMARK_MTORC1_SIGNALINGEAG3.3988e-030.2745image
ENSG00000105397.12,TYK2HNSCGSVA_HALLMARK_P53_PATHWAYEAG7.1173e-030.3528image
chr19:10351193-10352385:-HNSCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER4.1010e-040.4600image
chr19:10351193-10352385:-KICHGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.3673e-020.4543image
ENSG00000105397.12,TYK2KICHGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.3673e-020.4543image
chr19:10351193-10352385:-KIRCGSVA_HALLMARK_MYC_TARGETS_V1EER5.4177e-040.2887image
ENSG00000105397.12,TYK2KIRCGSVA_HALLMARK_DNA_REPAIREAG8.3344e-040.2793image
ENSG00000105397.12,TYK2KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG9.7354e-040.3911image
chr19:10351193-10352385:-KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEER9.7354e-040.3911image
ENSG00000105397.12,TYK2LAMLGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.9787e-02-0.1929image
chr19:10351193-10352385:-LGGGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.3249e-030.2525image
ENSG00000105397.12,TYK2LGGGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG6.4929e-040.2652image
ENSG00000105397.12,TYK2LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.3423e-02-0.4083image
ENSG00000105397.12,TYK2LUADGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG7.3524e-030.2152image
chr19:10351193-10352385:-LUADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER4.2136e-030.2332image
chr19:10351193-10352385:-LUSCGSVA_HALLMARK_MITOTIC_SPINDLEEER1.8481e-020.1867image
ENSG00000105397.12,TYK2LUSCGSVA_HALLMARK_MITOTIC_SPINDLEEAG9.0400e-030.2058image
chr19:10362903-10364437:-OVGSVA_HALLMARK_APICAL_SURFACEEER4.9980e-020.3120image
chr19:10358306-10359029:-OVGSVA_HALLMARK_PROTEIN_SECRETIONEER2.6936e-020.2444image
ENSG00000105397.12,TYK2OVGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.2994e-030.2504image
chr19:10351193-10352385:-OVGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER2.3775e-030.2749image
chr19:10351193-10352385:-PAADGSVA_HALLMARK_GLYCOLYSISEER4.5156e-030.3990image
ENSG00000105397.12,TYK2PAADGSVA_HALLMARK_GLYCOLYSISEAG4.5156e-030.3990image
chr19:10351193-10352385:-PCPGGSVA_HALLMARK_PEROXISOMEEER1.2475e-020.4015image
ENSG00000105397.12,TYK2PCPGGSVA_HALLMARK_PEROXISOMEEAG2.0163e-020.3755image
ENSG00000105397.12,TYK2SARCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG3.4950e-020.2318image
ENSG00000105397.12,TYK2SKCMGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG3.8621e-02-0.2443image
chr19:10351193-10352385:-SKCMGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER3.2630e-02-0.2539image
chr19:10362903-10364437:-STADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER3.6524e-030.3338image
ENSG00000105397.12,TYK2STADGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.4581e-030.2444image
chr19:10358306-10359029:-STADGSVA_HALLMARK_MITOTIC_SPINDLEEER6.9508e-040.3437image
ENSG00000105397.12,TYK2THCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.2860e-02-0.3246image
ENSG00000105397.12,TYK2THYMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG1.1150e-020.2541image
chr19:10351193-10352385:-THYMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER9.7056e-030.2601image
chr19:10351193-10352385:-UCSGSVA_HALLMARK_UV_RESPONSE_DNEER4.3841e-02-0.4148image
ENSG00000105397.12,TYK2UCSGSVA_HALLMARK_UV_RESPONSE_DNEAG4.4088e-02-0.4144image


Top

7. Enriched editing regions and drugs for TYK2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr19:10351193-10352385:-ACCBI.D1870EER1.1372e-02-0.4795image
ENSG00000105397.12,TYK2ACCBI.D1870EAG1.1372e-02-0.4795image
ENSG00000105397.12,TYK2BLCABIRB.0796EAG4.8290e-030.2238image
chr19:10351193-10352385:-BLCABIRB.0796EER6.6346e-030.2165image
chr19:10351193-10352385:-BRCAEHT.1864EER2.2660e-04-0.2652image
ENSG00000105397.12,TYK2BRCAEHT.1864EAG7.3680e-04-0.2397image
ENSG00000105397.12,TYK2CESCCCT007093EAG1.9456e-020.2009image
chr19:10351193-10352385:-CESCAZD6244EER1.8645e-02-0.2030image
ENSG00000105397.12,TYK2COADAZD.0530EAG5.2702e-03-0.4382image
chr19:10358306-10359029:-ESCAFH535EER1.1093e-02-0.3062image
ENSG00000105397.12,TYK2ESCAErlotinibEAG1.2440e-03-0.3013image
chr19:10362903-10364437:-ESCACHIR.99021EER9.5316e-03-0.3268image
chr19:10351193-10352385:-ESCABI.D1870EER2.7886e-02-0.2475image
ENSG00000105397.12,TYK2GBMAZD6244EAG1.3031e-020.2683image
chr19:10351193-10352385:-GBMBosutinibEER1.0909e-020.2748image
chr19:10351193-10352385:-HNSCIPA.3EER4.6813e-020.2693image
ENSG00000105397.12,TYK2HNSCIPA.3EAG2.9285e-030.3872image
ENSG00000105397.12,TYK2KICHAZD6244EAG4.6688e-02-0.4284image
chr19:10351193-10352385:-KICHAZD6244EER4.6688e-02-0.4284image
chr19:10351193-10352385:-KIRCImatinibEER3.8250e-030.2429image
ENSG00000105397.12,TYK2KIRCBMS.509744EAG2.2869e-03-0.2558image
ENSG00000105397.12,TYK2KIRPCCT018159EAG1.5788e-030.3760image
chr19:10351193-10352385:-KIRPCCT018159EER1.5788e-030.3760image
ENSG00000105397.12,TYK2LAMLAS601245EAG1.1126e-02-0.2370image
chr19:10351193-10352385:-LGGAP.24534EER3.1903e-030.2325image
ENSG00000105397.12,TYK2LGGAP.24534EAG2.3495e-030.2374image
ENSG00000105397.12,TYK2LIHCBAY.61.3606EAG2.8929e-040.5694image
chr19:10351193-10352385:-LIHCBAY.61.3606EER4.3051e-020.3440image
ENSG00000105397.12,TYK2LUADMethotrexateEAG1.5519e-020.1947image
chr19:10351193-10352385:-LUADBryostatin.1EER2.9638e-02-0.1783image
ENSG00000105397.12,TYK2LUSCCEP.701EAG1.1839e-020.1986image
chr19:10351193-10352385:-LUSCElesclomolEER9.1283e-030.2062image
chr19:10351193-10352385:-OVLapatinibEER7.1996e-03-0.2442image
chr19:10362903-10364437:-OVDoxorubicinEER4.4597e-020.3193image
chr19:10358306-10359029:-OVCamptothecinEER6.9216e-030.2961image
ENSG00000105397.12,TYK2OVA.770041EAG1.5536e-03-0.2596image
chr19:10351193-10352385:-PAADBosutinibEER3.4562e-030.4138image
ENSG00000105397.12,TYK2PAADBosutinibEAG3.4562e-030.4138image
chr19:10351193-10352385:-PCPGCisplatinEER1.2533e-020.4012image
ENSG00000105397.12,TYK2PCPGCisplatinEAG1.8072e-020.3816image
chr19:10351193-10352385:-SARCIPA.3EER1.1145e-020.2790image
ENSG00000105397.12,TYK2SARCGNF.2EAG5.5237e-04-0.3711image
chr19:10351193-10352385:-SKCMA.443654EER4.3025e-03-0.3349image
ENSG00000105397.12,TYK2SKCMA.443654EAG5.8772e-03-0.3216image
chr19:10362903-10364437:-STADAS601245EER2.3677e-02-0.2628image
chr19:10351193-10352385:-STADKIN001.135EER1.6923e-02-0.2420image
chr19:10368898-10369898:-STADElesclomolEER1.2826e-020.4224image
chr19:10358306-10359029:-STADAZD.2281EER1.3120e-030.3267image
chr19:10351193-10352385:-TGCTJNJ.26854165EER1.1130e-02-0.3751image
ENSG00000105397.12,TYK2TGCTJNJ.26854165EAG1.1337e-02-0.3702image
ENSG00000105397.12,TYK2THCAAP.24534EAG5.4034e-030.3915image
chr19:10351193-10352385:-THYMGW.441756EER4.0439e-03-0.2879image
ENSG00000105397.12,TYK2THYMGW.441756EAG2.8284e-03-0.2971image
chr19:10351193-10352385:-UCECBexaroteneEER1.3085e-02-0.3297image
ENSG00000105397.12,TYK2UCECAZD6244EAG8.3738e-03-0.3402image
ENSG00000105397.12,TYK2UCSBleomycinEAG3.2288e-02-0.4380image
chr19:10351193-10352385:-UCSBleomycinEER3.1937e-02-0.4388image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType
chr19:10358306-10359029:-ENST00000264818.9P29597DB08877RuxolitinibSmallMoleculeDrug
chr19:10358306-10359029:-ENST00000264818.9P29597DB08895TofacitinibSmallMoleculeDrug
chr19:10358306-10359029:-ENST00000264818.9P29597DB11817BaricitinibSmallMoleculeDrug
chr19:10358306-10359029:-ENST00000264818.9P29597DB12010FostamatinibSmallMoleculeDrug
chr19:10358306-10359029:-ENST00000264818.9P29597DB14973AbrocitinibSmallMoleculeDrug
chr19:10358306-10359029:-ENST00000264818.9P29597DB16650DeucravacitinibSmallMoleculeDrug
chr19:10358306-10359029:-ENST00000525621.4P29597DB08877RuxolitinibSmallMoleculeDrug
chr19:10358306-10359029:-ENST00000525621.4P29597DB08895TofacitinibSmallMoleculeDrug
chr19:10358306-10359029:-ENST00000525621.4P29597DB11817BaricitinibSmallMoleculeDrug
chr19:10358306-10359029:-ENST00000525621.4P29597DB12010FostamatinibSmallMoleculeDrug
chr19:10358306-10359029:-ENST00000525621.4P29597DB14973AbrocitinibSmallMoleculeDrug
chr19:10358306-10359029:-ENST00000525621.4P29597DB16650DeucravacitinibSmallMoleculeDrug
chr19:10362903-10364437:-ENST00000264818.9P29597DB08877RuxolitinibSmallMoleculeDrug
chr19:10362903-10364437:-ENST00000264818.9P29597DB08895TofacitinibSmallMoleculeDrug
chr19:10362903-10364437:-ENST00000264818.9P29597DB11817BaricitinibSmallMoleculeDrug
chr19:10362903-10364437:-ENST00000264818.9P29597DB12010FostamatinibSmallMoleculeDrug
chr19:10362903-10364437:-ENST00000264818.9P29597DB14973AbrocitinibSmallMoleculeDrug
chr19:10362903-10364437:-ENST00000264818.9P29597DB16650DeucravacitinibSmallMoleculeDrug
chr19:10362903-10364437:-ENST00000525621.4P29597DB08877RuxolitinibSmallMoleculeDrug
chr19:10362903-10364437:-ENST00000525621.4P29597DB08895TofacitinibSmallMoleculeDrug
chr19:10362903-10364437:-ENST00000525621.4P29597DB11817BaricitinibSmallMoleculeDrug
chr19:10362903-10364437:-ENST00000525621.4P29597DB12010FostamatinibSmallMoleculeDrug
chr19:10362903-10364437:-ENST00000525621.4P29597DB14973AbrocitinibSmallMoleculeDrug
chr19:10362903-10364437:-ENST00000525621.4P29597DB16650DeucravacitinibSmallMoleculeDrug